Abstract

SULFOBUTYLETHER Î’-CYCLODEXTRINE (SBE-Î’-CD): A BREAKTHROUGH FOR SOLUBILITY ENHANCEMENT

*Prathamesh P. Walke and Dr. Swaroop R. Lahoti

.

Abstract

More than 40% of medications have poor bioavailability, and a key contributing factor to this is the low water solubility of the API. A number of poorly soluble lipophilic medications can combine with oligosaccharides like cyclodextrins (CDs) to produce water-soluble inclusion complexes. Consequently, CDs are employed to improve the bioavailability and water solubility. Depending on whether the parent, or natural, CDs have six, seven, or eight glucopyranose units, they are referred to as alpha, beta, or gamma CDs respectively. Many derivatives with better features are found in addition to these parent CDs. One of the most recently developed and specially modified derivatives of CD is sulfobutylether-β-cyclodextrin (SBE-β-CD), a compound whose structure is logically designed to enhance interaction and increase safety while enhancing the solubility and stability of active components SBE-β-CD's physico-chemical characteristics offer the perfect medium for solubilizing medications with limited water solubility by nature. An examination of the literature indicates that there are numerous reviews on CDs; however, there isn't a review specifically on SBE-β-CD. For this reason, we focused our evaluation on the qualities, safety concerns, research, patents, and regulatory elements of SBE-β-CD.

Keywords: Cyclodextrins, Solubility, Dissolution, Bioavailability, Glucopyranose unit.